Citizens JMP lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $22 from $26 and keeps an Outperform rating on the shares. Bicycle reported Q1 results and provided corporate milestones, including the initiation of the Phase 1/2 Duravelo-3 trial in NECTIN4-amplified breast cancer, which will enroll roughly 60 patients, the analyst tells investors in a research note. The firm continues to believe Bicycle shares represent a unique investment opportunity.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCYC:
- Bicycle Therapeutics Reports Q1 2025 Progress and Financials
- Bicycle Therapeutics price target lowered to $15 from $40 at Barclays
- Bicycle Therapeutics: Promising Advancements and Strong Financial Position Justify Buy Rating
- Promising Developments in Bicycle Therapeutics’ Pipeline Bolster Buy Rating
- Bicycle Therapeutics reports Q1 EPS (88c), consensus (81c)
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue